Resource Use and Costs Related to Hematological Complications of Chemotherapy: Cost of Illness Study Based on Data from Balkan Country with Recent History of Socioeconomic Transition.

Autor:	Kostić M; Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Janković S; Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Desnica J; Department of Dentistry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Lukić S; Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Mijailović S; Department of Medical Statistics and Informatics, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Anđelković M; Department of Biochemistry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Pirković MS; Department of Biochemistry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Milovanović O; Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Spasić M; Department of Surgery, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Vojinović T; Pharmacy Study Program, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro., Zečević DR; Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Jazyk:	angličtina
Zdroj:	Iranian journal of public health [Iran J Public Health] 2022 Nov; Vol. 51 (11), pp. 2573-2581.
DOI:	10.18502/ijph.v51i11.11175
Abstrakt:	Background: The administration of chemotherapy positively correlates with diverse adverse drug reactions, including the significant impact of hematological hazards such as anemia, leukopenia-neutropenia, thrombocytopenia, and pancytopenia. This pilot pharmacoeconomic study aimed to estimate the total direct costs of treating hematological toxicity induced by chemotherapy and its main determinants. Methods: The study was conducted as a retrospective cost of illness study using the "from bottom to the top" approach from the perspective of the Republic Health Insurance Fund. This study included 88 patients treated due to developing at least one episode of one of the types of hematological complications of cytostatics in 2018 at the Oncology Clinic of the University Clinical Center Kragujevac, Kragujevac, the Republic of Serbia. Results: Among cancer patients who developed haematological toxicity, treating pancytopenia was most demanding in a pharmacoeconomic manner compared to neutropenia and thrombocytopenia, with an estimated value of direct costs of 264,14, 178,19 and 157,76 euros per patient per year respectively. Regarding total direct costs, the main determinants were the costs of drugs, their parenteral administration, and costs due to hospitalization. Conclusion: Due to the rising cancer incidence and obligatory hospital treatment of hematological toxicity induced by chemotherapy, the identification of the pharmacoeconomic aspects of the treatment of these complications is needed. Future research should focus on the development of new modalities of treatment regarding patient characteristics anticipating high costs. Competing Interests: Conflict of interest The authors declare that there is no conflict of interest. (Copyright © 2022 Kostić et al. Published by Tehran University of Medical Sciences.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu